- Home
- RGNX
RGNX
REGENXBIO Inc.
as of 12-31-2025 3:38pm EST
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 732.0M | IPO Year: | 2015 |
| Target Price: | $30.78 | AVG Volume (30 days): | 662.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.04 - $15.41 | Next Earning Date: | 11-06-2025 |
| Revenue: | $161,318,000 | Revenue Growth: | 91.30% |
| Revenue Growth (this year): | 132.8% | Revenue Growth (next year): | 45.32% |
AI-Powered RGNX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare RGNX vs Leading Stocks
See how RGNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RGNX REGENXBIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.